A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

The average one-year price target for Travere Therapeutics (NasdaqGM:TVTX) has been revised to $42.33 / share. This is an ...

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life ...

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based ...

Celebrations may be in order for Travere Therapeutics, Inc. (NASDAQ:TVTX) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. Consensus ...

In FSGS, podocytes are damaged, like a net with torn holes, allowing protein to leak into the urine, creating a harmful ...

Travere’s financial performance in Q3 2025 exceeded expectations, with total revenue of $164.9 million compared to the forecast of $105.57 million. The company reported a net income of $25.7 million, ...

Travere Therapeutics Inc (TVTX) stock has reached a new 52-week high, hitting 28.75 USD. With a market capitalization of $2.55 billion, the company has caught analysts’ attention, with price targets ...

Travere Therapeutics (TVTX) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to a loss of $0.7 per share a year ago ...

Travere Therapeutics Inc. reported a strong financial performance for the third quarter of 2025, with earnings per share (EPS) of $0.59, significantly surpassing the forecasted loss of $0.29. The ...